Diferencia entre revisiones de «Bupropion toxicity»
Sin resumen de edición |
|||
| Línea 1: | Línea 1: | ||
==Background== | ==Background== | ||
* | *[[Bupropion]] is a norepinephrine/dopamine reuptake inhibitor used for depression, ADHD, and smoking cessation | ||
*Toxicity occurs with ingestion of >450mg/d | *Toxicity occurs with ingestion of >450mg/d | ||
==Clinical Features== | ==Clinical Features== | ||
*Agitation | *[[Agitation]] | ||
*Dizziness | *[[Dizziness]] | ||
*Tremor | *Tremor | ||
*[[Nausea/vomiting]] | *[[Nausea/vomiting]] | ||
*Drowsiness | *Drowsiness/[[lethargy]] | ||
*Tachycardia | *Tachycardia | ||
*[[Seizure]] | *[[Seizure]] | ||
**May develop in isolation from other symptoms | **May develop in isolation from other symptoms | ||
**Develops within first 1-4hr for regular-release, up to 8hr for delayed release forms | **Develops within first 1-4hr for regular-release, up to 8hr for delayed release forms | ||
*[[Hypotension]] and [[ | *[[Hypotension]] and [[cardiogenic Shock]] | ||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
| Línea 23: | Línea 19: | ||
==Evaluation== | ==Evaluation== | ||
*CBC, CMP | *CBC, CMP | ||
*ECG to eval for [[QT prolongation]] | *[[ECG]] to eval for [[QT prolongation]] | ||
==Management== | ==Management== | ||
*[[GI decontamination]] | *[[GI decontamination]] | ||
**Consider whole-bowel irrigation for sustained-release formulations | **Consider whole-bowel irrigation for sustained-release formulations | ||
*[[Seizure | *[[Seizure|Seizure Treatment]] | ||
**[[Benzos]] are 1st line | **[[Benzos]] are 1st line | ||
**[[ | **[[Barbiturates]] are 2nd line | ||
==Disposition== | ==Disposition== | ||
| Línea 36: | Línea 32: | ||
==See Also== | ==See Also== | ||
*[[Bupropion]] | |||
==References== | ==References== | ||
[[Category:Toxicology]] | [[Category:Toxicology]] | ||
Revisión del 23:34 26 dic 2016
Background
- Bupropion is a norepinephrine/dopamine reuptake inhibitor used for depression, ADHD, and smoking cessation
- Toxicity occurs with ingestion of >450mg/d
Clinical Features
- Agitation
- Dizziness
- Tremor
- Nausea/vomiting
- Drowsiness/lethargy
- Tachycardia
- Seizure
- May develop in isolation from other symptoms
- Develops within first 1-4hr for regular-release, up to 8hr for delayed release forms
- Hypotension and cardiogenic Shock
Differential Diagnosis
Evaluation
- CBC, CMP
- ECG to eval for QT prolongation
Management
- GI decontamination
- Consider whole-bowel irrigation for sustained-release formulations
- Seizure Treatment
- Benzos are 1st line
- Barbiturates are 2nd line
Disposition
- Consider discharge if asymptomatic after 8hr for regular-release ingestions